BofA/Merrill Lynch reinstated coverage on Regeneron Pharma (NASDAQ: REGN) with a Buy ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

New Coverage

Roth Keeps Regeneron (REGN) at 'Buy' Following Q4 Numbers, Outlook; VISTA, OUTLOOK Still in FocusFebruary 12, 2014 1:26 PM Regeneron Pharma (REGN) PT Raised to $410 at Deutsche BankFebruary 11, 2014 2:32 PM Regeneron Pharma (REGN) May Have Upside From Taxes - AnalystFebruary 11, 2014 10:36 AM UPDATE: Regeneron Pharma (REGN) Easily Tops Q4 EPS Views; Guides FY14 EYLEA SalesFebruary 11, 2014 6:32 AM